chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I am feeling pain in my leg you know, It's like, I can't even walk very well; It's like getting worst.; My left leg on the bottom, Like strong pain in my bottom. I can't really walk very well.; This is a spontaneous report from contactable consumer. This consumer (Patient) reported.  A patient of an unspecified age and gender received second dose of BNT162B2 (solution for injection, Lot number: unknown) via an unspecified route of administration on 27Aug2021, as dose 2, single for Covid-19 immunization. Medical history and concomitant medications were not report-ed. The patient received first dose of BNT162B2 (solution for injection, Lot number: unknown) via an unspecified route of administration on an unknown date in 2021, as dose 1, single for Covid-19 immunization. The patient stated that after the 2nd shot, patient don't know the vaccine is, What is causing it or left leg on the bottom, Like strong pain in bottom. Patient can't really walk very well. Patient don't know if it has to do with the vaccine. The patient wanted to make sure, It's not some-thing serious cause. Patient can't even walk very well. So, It's like getting worst. If, It has anything to do with vaccine or something different. The patient also stated that they would see, and go to emergency room now. They just want someone, who knows that, Someone can give advice, this is serious or not. The patient was requested to visit the Health care provider in case of emergency. The outcome of the events was reported as not recovered.   The lot number for the vaccine, BNT162B2, was not provided and would be requested during follow up.
Rash; Body aches; This is a spontaneous report from a non-contactable other healthcare professional (patient).   A 62-year-old male patient received bnt162b2 (BNT162B2), via an unspecified route of administration, administered in Arm Left on 25Feb2021 13:15, at the age of 62-years-old, (Batch/Lot number was not reported) as DOSE 1, SINGLE for COVID-19 immunization.  Medical history included rash (patient states that he gets a rash whenever he contracts a VIRUS), covid-19 from an unknown date (prior vaccination: yes). The patient's concomitant medications were not reported.  On 27Feb2021 07:00, the patient experienced rash and body aches. The outcome of the events was recovered on 01Mar2021.  The patient was not tested for COVID-19 post vaccination. No treatment was received for the events.     No follow-up attempts are possible; information about lot/batch number cannot be obtained.
26JAN96 pt recvd vax & 5FEB96 devel severe case of itching & hives over entire body;denies any other adverse rxns;visit to MD who prescribed Pred;7FEB96 appears to have helped & hives are subsiding
sore arm  as heck as for a good 24 hours; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.     Linked case(s) involving the same patient:  US2022AMR153124   Additional Information: GSK receipt date: 23-OCT- 2022 Reporters comment: This case was reported by a consumer via interactive digital media. The patient received first dose of Shingrix vaccine experienced sore arm heck for 24 hours. Follow-up would not possible, as no contact, details were available. For tolerance of second dose, refer case US2022AMR153124.; Sender's Comments:  US-GSK-US2022AMR153124:Same reporter
Pt experienced syncope w/ flushing/sweating, light headed and dizziness.  VSS.  Pt given water and indicated that he is feeling better.  Pt stable and released from vaccination site.
12/25/22 he had a fever of 101.7 and was inconsolable. We took him into the urgent care. He was diagnosed with an ear infection and was started on antibiotics. Late the next day, he seemed to be improving. He has recovered.
This child had local soft edema above, below, and medial to the left patellar as well as the left thigh. No induration, no significant erythema, no fever, full range of motion and weight bearing. Noted 24 hours after vaccine.
more than 35 days since got the first dose/ not gotten the second one (was scheduled to get it on 11Jun2021).; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (more than 35 days since got the first dose/ not gotten the second one (was scheduled to get it on 11Jun2021).) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (more than 35 days since got the first dose/ not gotten the second one (was scheduled to get it on 11Jun2021).). At the time of the report, PRODUCT DOSE OMISSION ISSUE (more than 35 days since got the first dose/ not gotten the second one (was scheduled to get it on 11Jun2021).) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment medications were provided.
Pretty bad rash, started on each side of nose, now its on both jaws and checks and upper part of nose and left corner of mouth upper and lower lip
Systemic: Chills-Mild, Additional Details: Patient said she felt sensation like ants were crawling on the arm that the inject was given but that sensation and chills went away about 40 mins after she had the vaccine. She reported that she felt better and did not have either effects anymore.
Approx. 3 hours after being vaccinated. Developed confusion, dizziness, and blurred vision. Went to ER. BP noted to be 163/100. After one hour and a half, BP in the 120's systolic and 90's diastolic. Continued to have blurred vision. Blood pressure became labile and continued to be in the range of 160's over 100's to 130/90's. After 48 hours, vision no longer blurred, Blood pressure returned to normal baseline and maintained.  Took BP for over one week after, morning, noon, and night on the Left arm and Right arm. My BP stayed in the 117/70-120/80 range. Wanted to make sure I had no underlying hypertension. No other adverse issues.
Pt recv vax on 12/7/98; on same day pt exp swollen hands, aching all over & vomiting; dx=intestinal infection; tx=Cefzil, Phenergan, Leusin
minor injection site soreness; This is a spontaneous report from a contactable consumer (patient). A 62-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: El324? (as reported)), via an unspecified route of administration at the left arm on 08Jan2021 at 13:00 (01:00 PM) at a single dose for COVID-19 immunization. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had no medical history. The patient had no allergies to medications, food, or other products. Concomitant medication included levothyroxine sodium (UNITHROID) that was received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced minor injection site soreness on Jan2021. The event was reported as non-serious. The patient has not been tested for COVID-19 since the vaccination. The outcome of the event was recovered on Jan2021.
~13 hours post vaccination, symptoms consistent with acute intermittent porphyria exacerbation (attack) developed: severe abdominal pain, nausea, brain fog. Porphyria symptoms responded to porphyria-specific treatment (IV infusion with hemin (Panhematin) on both 2/10/21 and 2/11/21; analgesics). Porphyria symptoms lasted until 2/12/21. -On 2/10/21 also typical COVID-19-vaccine side effects: muscle and joint pain, fever (101.2F), chills. These resolved within one day.  Previous mild COVID-19 (8 months prior to vaccination). Infection is a known trigger of porphyria attacks. Vaccination does not usually trigger porphyria symptoms.
Patient states vaccine was administered too far down her arm and was not given in the deltoid, but the bicept muscle. Complains of 2 inch red, warm hard area on bicept
Can not move my arm at all; Most painful vaccine iv'e ever gotten; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (Can not move my arm at all) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse effect (No medical history was reported).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE MOVEMENT IMPAIRMENT (Can not move my arm at all) (seriousness criterion disability) and VACCINATION SITE PAIN (Most painful vaccine iv'e ever gotten). At the time of the report, VACCINATION SITE MOVEMENT IMPAIRMENT (Can not move my arm at all) and VACCINATION SITE PAIN (Most painful vaccine iv'e ever gotten) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Case comment: Very limited information regarding these events has been provided at this time.  Further information has been requested.   Reporter did not allow further contact; Reporter's Comments: Very limited information regarding these events has been provided at this time.  Further information has been requested.
I was giving a pt a flu shot and a TWINRIX shot. Someone had mixed in a 5/8 inch needle into the 1 inch needle box. So I gave the TWINRIX shot 1st and then noticed that it was shorter than the 1 inch needle on the second flu shot. I did give both at a 90 degree angle. This is what facts and comparison said "Although subcutaneous administration is not recommended in labeling (antibody response may be suboptimal), the product labeling suggests that subcutaneous administration may be used in patients at risk for hemorrhage (including those with thrombocytopenia)." I called the CDC they said. That if Hepatitis B is given SQ it should be repeated but the Hepatitis A does not need to be repeated. I asked again about the 5/8 inch needle part pt's weighing more than 152 need 1 inch to 1.5 inch needle. Reach out to Dr office (pt's PCP) they said okay to revaccinate with Hepatitis B.
This spontaneous report was received from a registered nurse concerning a patient of unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date, reported as in the past, the patient was vaccinated with two doses of VARIVAX (dose, route, anatomical location or lot# were not informed). Concomitant medications were not provided. On an unknown date, also reported as in the past, the patient experienced chickenpox. The outcome of chickenpox was unknown. The relatedness between the event and VARIVAX was not provided. Additional information has been requested.
Infected; Little Lump; Warm to touch; Swelling; It has gotten bigger at least 3 inches long and 2inches wide; red reaction in the area I got the injection; Chills; Hives/urticaria generalized; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INFECTION (Infected), VACCINATION SITE MASS (Little Lump), VACCINATION SITE WARMTH (Warm to touch), URTICARIA (Hives/urticaria generalized) and VACCINATION SITE ERYTHEMA (red reaction in the area I got the injection) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy, Allergy (Yeast (Candida)), Asthma, Hay fever, Anxiety and High cholesterol. Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) from 1997 to an unknown date for Anxiety, SIMVASTATIN (STATIN [SIMVASTATIN]) for High cholesterol.    On 29-Jan-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced URTICARIA (Hives/urticaria generalized) and CHILLS (Chills). On 29-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (red reaction in the area I got the injection). On 11-Feb-2021, the patient experienced VACCINATION SITE MASS (Little Lump), VACCINATION SITE WARMTH (Warm to touch), VACCINATION SITE SWELLING (Swelling) and VACCINATION SITE ERYTHEMA (It has gotten bigger at least 3 inches long and 2inches wide). On an unknown date, the patient experienced VACCINATION SITE INFECTION (Infected). On 11-Mar-2021, URTICARIA (Hives/urticaria generalized) and CHILLS (Chills) had resolved. At the time of the report, VACCINATION SITE INFECTION (Infected), VACCINATION SITE MASS (Little Lump), VACCINATION SITE WARMTH (Warm to touch), VACCINATION SITE ERYTHEMA (red reaction in the area I got the injection), VACCINATION SITE SWELLING (Swelling) and VACCINATION SITE ERYTHEMA (It has gotten bigger at least 3 inches long and 2inches wide) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment provided included an unknown antihistamine and antibiotics.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Added email address, past medical history, patient height, weight, race details, concomitant medications information, and events.
Patient had what she described as a "severe headache" accompanied with "blisters" that developed a few inches below the actual injection site.
Patient had erythema, pain, swelling of 8" diameter on the right upper extremity, after right deltoid injection. Apparent cellulitis.
On 7/15 Received KINRIX in L arm - On 7/16 on awakening at 7 AM mom noted raised rash at site of injection and also chest/arms/legs/back/buttocks. Seen in office at 9:30 AM - Dx urticaria/ no S/S SOB/no wheezing.
Huge Knot; swelling; itchiness; Tightness; Tenderness; A spontaneous report was received from a consumer concerning a 45-years-old  patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events tenderness/injection site pain, huge knot/injection site mass, swelling/injection site swelling, itchiness/injection site pruritus, tightness/muscle tightness.  The patient's medical history was not provided. Concomitant medications reported were medroxy progestrone, Bladder Pills., Menopause Medications for drug use for unknown indication.  On 10 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 038K20A) intramuscularly for prophylaxis of COVID-19 infection.  On 10 Feb 2021, the patient experienced the event(s) tenderness. On 19 Feb 2021, the patient experienced the event(s) huge knot, swelling, itchiness, tightness.  Treatment details included Ibuprofen and diphenhydramine.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), tenderness, huge knot, swelling, itchiness, tightness was unknown.
Both arms and tops of hands were burning; Both arms and tops of hands appear reddened the day after vaccine; Showering the warm water felt like pins and needles; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0186) via an unspecified route of administration in the left arm on 05Aug2021 at 16:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia. The patient had known allergies to dust and shellfish. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient also took epinephrine (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 06Aug2021 at 11:00, the patient experienced both arms and tops of hands were burning and reddened the day after vaccine. When she showering the warm water felt like pins and needles on her skin. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of events both arms and tops of hands were burning, both arms and tops of hands were reddened and showering the warm water felt like pins and needles were not resolved at the time of this report.
Right arm red, tender and warm to touch. Started nine days after injection of vaccine. Redness spread more the next day as reported. Primary doctor called and no treatment given.
This spontaneous report was received from a doctor of pharmacy concerning an approximately 72 year old female patient. On 02-SEP-2013, the patient was vaccinated with 0.65 milliliter (ml) of ZOSTAVAX (lot number and expiry date were reported as J002869 and 14-JUN-2014 respectively), subcutaneously. No concomitant therapy was reported. Approximately on an unknown date in September 2013, the patient experienced pain and numbness in the lower bottom of spine that goes down her right leg that began after patient received ZOSTAVAX. The patient informed the reporter that the pain and numbness comes and goes and she cannot walk when she has the pain and numbness. On 05-SEP-2013, the patient could not walk but it was better on the date of report (on 06-SEP-2013). The patient sought medical attention (called the pharmacist). The patient was treated with a heating pad and ALEVE. It was unspecified if any lab tests were performed. The outcome of pain and numbness in the lower bottom of spine that goes down her right leg was unknown. The relatedness for the events was unknown for ZOSTAVAX. Additional information has been requested.
Pain, heat, redness, swelling, inflammation, wrapping around arm but starting but 2-3 inches below where the vaccine was injected, might not even be related and coincidental
8 patients received doses past the expiration date; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (8 patients received doses past the expiration date) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (8 patients received doses past the expiration date). In 2021, EXPIRED PRODUCT ADMINISTERED (8 patients received doses past the expiration date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Vaccines were administered to 8 patient and these were the dates of administration. On 24 Sep 2021 (3 patients), 1 Oct 2021 (2 patients), 8 Oct 2021 (3 patients)  No concomitant products were reported. No treatment information was reported by the reporter.
This spontaneous report as received from a physician refers to two patients of unknown age. The patient were vaccinated with a dose of ZOSTAVAX (lot #, dose and route not reported) on unspecified dates. No other co-suspects were reported. No concomitant medications were reported. The physician reported that the patients were administered ZOSTAVAX and subsequently developed shingles on unspecified dates. No treatment information was reported. The patients sought unspecified medical attention and the physician was aware of both cases. The outcome of shingles is unknown. The relatedness for shingles was not provided for ZOSTAVAX. Additional information has been requested.
COVID-19; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (COVID-19) in a 72-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 prophylaxis.     Concurrent medical conditions included High cholesterol, Thyroid disorder and Urinary retention. Concomitant products included TAMSULOSIN HYDROCHLORIDE (FLOMAX [TAMSULOSIN HYDROCHLORIDE]) for Urinary retention.    On 19-Sep-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 06-Dec-2022,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced COVID-19 (COVID-19). In December 2022, COVID-19 (COVID-19) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2022, SARS-CoV-2 test: Negative.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   The patient was taking a generic statin for high cholesterol and medication for thyroid.  The patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  The patient received Moderna COVID-19 Vaccine 1st dose on 05-FEB-2021, 2nd dose on 04-MAR-2021, 1st booster on 01-APR-2021. Patient got mild COVID-19 on 06-DEC-2022, even after receiving bivalent booster. Symptoms experienced by patient included chills, achiness, headache, congestion of nose, cough and nasal drip. Patient came negative 9 or 10 days later. No treatment was given.   This case was linked to MOD-2021-304506 (Patient Link).
administration of improperly stored vaccines; This spontaneous report was received from a medical assistant referring to a 4 years old patient of unknown gender. Concomitant therapy included sterile diluent. Information about pertinent medical history and drug reaction/allergy was not provided.  On 31-AUG-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) (lot # T002848, expiration date 23-JAN-2022; strength, vaccine dosage detail and route of administration were not reported) for prophylaxis (product storage error). Current temperature excursion was 6 Fahrenheit degrees to 14 Fahrenheit degrees (10.56 Fahrenheit degrees) for 50 minutes. Previous temperature excursion was 6 Fahrenheit degrees to 14 Fahrenheit degrees (8.47 Fahrenheit degrees) for 30 minutes. No product quality complaint (PQC) was identified. Data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA000747: US-009507513-2009USA000777: US-009507513-2009USA000676: US-009507513-2009USA000699: US-009507513-2009USA000710:
First night severe reflux. Fatigue continuous. Neck and body pain continuous since vaccinated. Stuffy nose. (Note: seasonal allergies an issue). Flushing, no fever.
Father reported his son received a shot 1 hour ago and he returned to clinic for us to check his son.  Hives on face, trunk, axilla, groin and thighs.  Hives more dense around lips, no SOB, followed father's commands.  Capillary refill WNL.  Benadryl 25mg IM given and ambulance personnel arrived 5 minutes later and transported him to hospital.